Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Clyra Medical Technologies [Member] Common Stock [Member]	Clyra Medical Technologies [Member] Additional Paid-in Capital [Member]	Clyra Medical Technologies [Member] Retained Earnings [Member]	Clyra Medical Technologies [Member] AOCI Attributable to Parent [Member]	Clyra Medical Technologies [Member] Noncontrolling Interest [Member]	Clyra Medical Technologies [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Common Stock [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Additional Paid-in Capital [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Retained Earnings [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] AOCI Attributable to Parent [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Noncontrolling Interest [Member]	BioLargo Energy Technologies, Inc (BETI) [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2021													255,893,726
Balance at Dec. 31, 2021													$ 171,000	$ 143,718,000	$ (139,121,000)	$ (115,000)	$ (3,720,000)	$ 933,000
Sale of stock for cash (in shares)													6,703,789
Sale of stock for cash													$ 4,000	1,198,000	0	0	0	1,202,000
Issuance of common stock for services (in shares)													86,752
Issuance of common stock for services													$ 0	17,000	0	0	0	17,000
Stock option compensation expense													0	660,000	0	0	0	660,000
Clyra Medical Technologies, Inc. (Clyra) stock options issued for services	$ 0	$ 141,000	$ 0	$ 0	$ 0	$ 141,000
Noncontrolling interest allocation													0	(528,000)	0	0	528,000	0
Net loss													0	0	(1,652,000)	0	108,000	(1,544,000)
Foreign currency translation													$ 0	0	0	(8,000)	0	(8,000)
Balance (in shares) at Dec. 31, 2021													255,893,726
Balance at Dec. 31, 2021													$ 171,000	143,718,000	(139,121,000)	(115,000)	(3,720,000)	933,000
Net loss																		(3,724,000)
Foreign currency translation																		(70,000)
Balance (in shares) at Mar. 31, 2022													262,684,267
Balance at Mar. 31, 2022													$ 175,000	145,206,000	(140,773,000)	(123,000)	(3,084,000)	1,401,000
Sale of stock for cash (in shares)													5,011,570
Sale of stock for cash													$ 4,000	944,000	0	0	0	948,000
Issuance of common stock for services (in shares)													340,891
Issuance of common stock for services													$ 0	59,000	0	0	0	59,000
Stock option compensation expense													0	234,000	0	0	0	234,000
Clyra Medical Technologies, Inc. (Clyra) stock options issued for services	0	82,000	0	0	0	82,000
Noncontrolling interest allocation													0	(103,000)	0	0	103,000	0
Net loss													0	0	(1,228,000)	0	(105,000)	(1,333,000)
Foreign currency translation													$ 0	0	0	(3,000)	0	(3,000)
Balance (in shares) at Jun. 30, 2022													268,036,728
Balance at Jun. 30, 2022													$ 179,000	146,422,000	(142,001,000)	(126,000)	(3,086,000)	1,388,000
Sale of stock for cash (in shares)													6,207,084
Sale of stock for cash													$ 4,000	1,113,000	0	0	0	1,117,000
Issuance of common stock for services (in shares)													378,828
Issuance of common stock for services													$ 1,000	95,000	0	0	0	96,000
Stock option compensation expense													0	253,000	0	0	0	253,000
Clyra Medical Technologies, Inc. (Clyra) stock options issued for services	0	85,000	0	0	0	85,000
Noncontrolling interest allocation													0	(498,000)	0	0	498,000	0
Net loss													0	0	(504,000)	0	(343,000)	(847,000)
Foreign currency translation													$ 0	0	0	(59,000)	0	(59,000)
Balance (in shares) at Dec. 31, 2022													278,462,706
Balance at Dec. 31, 2022													$ 186,000	148,435,000	(143,594,000)	(149,000)	(2,867,000)	2,011,000
Sale of stock for cash (in shares)													4,201,402
Sale of stock for cash													$ 3,000	797,000	0	0	0	800,000
Issuance of common stock for services (in shares)													930,490
Issuance of common stock for services													$ 1,000	206,000	0	0	0	207,000
Issuance of common stock in exchange for Clyra shares (in shares)													527,983
Stock option compensation expense													$ 0	195,000	0	0	0	195,000
Clyra Medical Technologies, Inc. (Clyra) stock options issued for services	0	61,000	0	0	0	61,000
Warrant issued for interest													0	30,000	0	0	0	30,000
Clyra – sales of Series A Preferred Stock	0	0	0	0	225,000	225,000	$ 0	$ 0	$ 0	$ 0	$ 550,000	$ 550,000
Clyra – Series A Preferred Stock – dividend	0	0	0	0	(27,000)	(27,000)
Noncontrolling interest allocation													0	467,000	0	0	(467,000)	0
Net loss													0	0	(247,000)	0	(247,000)	(494,000)
Foreign currency translation													$ 0	0	0	(6,000)	0	(6,000)
Balance (in shares) at Dec. 31, 2022													278,462,706
Balance at Dec. 31, 2022													$ 186,000	148,435,000	(143,594,000)	(149,000)	(2,867,000)	2,011,000
Clyra – sales of Series A Preferred Stock						1,575,000						905,000
Net loss																		(3,628,000)
Foreign currency translation																		(12,000)
Balance (in shares) at Mar. 31, 2023													284,122,581
Balance at Mar. 31, 2023													$ 190,000	150,191,000	(143,841,000)	(155,000)	(2,833,000)	3,552,000
Sale of stock for cash (in shares)													2,677,169
Sale of stock for cash													$ 2,000	492,000	0	0	0	494,000
Issuance of common stock for services (in shares)													420,911
Issuance of common stock for services													$ 0	75,000	0	0	0	75,000
Stock option compensation expense													0	222,000	0	0	0	222,000
Clyra Medical Technologies, Inc. (Clyra) stock options issued for services	0	66,000	0	0	0	66,000
Clyra – sales of Series A Preferred Stock	0	0	0	0	1,062,000	1,062,000
Clyra – Series A Preferred Stock – dividend	0	0	0	0	(45,000)	(45,000)
Noncontrolling interest allocation													0	1,461,000	0	0	(1,461,000)	0
Net loss													0	0	(1,328,000)	0	(298,000)	(1,626,000)
Foreign currency translation													$ 0	0	0	(7,000)	0	(7,000)
Biolargo Energy Technology Inc. (BETI) offering							0	0	0	0	330,000	330,000
Balance (in shares) at Jun. 30, 2023													287,220,661
Balance at Jun. 30, 2023													$ 192,000	152,507,000	(145,169,000)	(162,000)	(3,245,000)	4,123,000
Sale of stock for cash (in shares)													1,190,223
Sale of stock for cash													$ 1,000	202,000	0	0	0	203,000
Issuance of common stock for services (in shares)													215,686
Issuance of common stock for services													$ 0	37,000	0	0	0	37,000
Stock option compensation expense													0	680,000	0	0	0	680,000
Clyra Medical Technologies, Inc. (Clyra) stock options issued for services	0	45,000	0	0	0	45,000
Clyra – sales of Series A Preferred Stock	0	0	0	0	288,000	288,000
Clyra – Series A Preferred Stock – dividend	0	0	0	0	(80,000)	(80,000)
Noncontrolling interest allocation													0	(68,000)	0	0	68,000	0
Net loss													0	0	(1,200,000)	0	(308,000)	(1,508,000)
Foreign currency translation													$ 0	$ 0	$ 0	$ 1,000	$ 0	$ 1,000
Biolargo Energy Technology Inc. (BETI) offering							$ 0	$ 0	$ 0	$ 0	$ 25,000	$ 25,000
Clyra Medical Technologies, Inc. (Clyra) stock option exercise	$ 0	$ 3,000	$ 0	$ 0	$ 0	$ 3,000